No curative drug treatment exists for<unk> s. Hematopoietic stem cell transplantation can be a curative treatment for a small group of patients, however<unk>  treatment is typically focused on symptom control and myelosuppressive drugs to help control the production of blood cells. The goal of treatment for ET and PV is prevention of thrombohemorrhagic complications. The goal of treatment for MF is amelioration of anemia, splenomegaly, and other symptoms. Low-dose aspirin is effective in PV and ET. Tyrosine kinase inhibitors like imatinib have improved the prognosis of CML patients to near-normal life expectancy. Recently, a JAK2 inhibitor, namely ruxolitinib, has been approved for use in primary myelofibrosis. Trials of these inhibitors are in progress for the treatment of the other<unk> s.
Myeloproliferative neoplasm
Lymphoproliferative disorders
Immunoproliferative disorder
Autoimmune neutropenia
Leukemoid reaction
Myelodysplastic syndrome
B-cell leukemia
B-cell lymphoma